Dr. Jessica McAlpine was born and raised in Vancouver. She did her medical training in the US, returning in 2006 to take a position at UBC and the BC Cancer Agency. She currently splits her time equally between clinical/surgical duties and translational research. She is part of the OVCARE research team (British Columbia’s Ovarian Cancer Research group) and Director of the OVCARE Tissue Bank. Her research focuses on specific subtypes of ovarian and endometrial cancers, and prevention.
Opportunistic salpingectomy for ovarian, fallopian tubal and peritoneal carcinoma risk reduction. Miller DM, McAlpine JN. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Last updated Aug 12, 2014.)
Population Distribution of Lifetime Risk of Ovarian Cancer in the U.S. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Menon U, Fasching PA, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, McAlpine JN, Huntsman D, Wu AH, Berchuck A, Pike MC, Pharoah PDP. Obstetrics and Gynecology (Under Review).
Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Kwon JS, McAlpine JN, Hanley G, Finlayson S, Cohen T, Miller DM, Gilks CB, Huntsman DG. Obstet Gynecol (Accepted, minor revisions).
Intratumoral heterogeneity in an ovarian low-grade serous carcinoma: Implications for targeted therapy. Tone A, McConechy M, Yang W, Ding J, Yip S, Kong E, Wong K-K, Gershenson D, Mackay H, Shah S, Gilks CB, Tinker A, McAlpine JN, Clarke B, Huntsman D. BMC Cancer (In Press).
TITAN: Inference of copy number architectures in clonal cell populations from tumor whole genome sequence data. Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melynk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Genome Research (Epub Jul 24, 2014) PMID: 25060187.
Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu Y-G, Lazzaroni-Tealdi E, Barad DH. PLOS One 2014 Jul 18;9(7):e102370. PMID: 25036526.
Expanding the Morphological Spectrum of Differentiated VIN (dVIN) Through Detailed Mapping of Cases with p53 Loss. Singh N, Leen SL, Han G, Faruqi A, Kokka F, Rosenthal A, Jiang J, Kim R, McAlpine JN, Gilks CB. Am J Surg Pathol (Epub Jul 14 2014) PMID: 25025443.
MDM2 amplification is a frequent genetic aberration in Mullerian adenosarcomas.Lee, J-C, Liang C-W, Davidson B, Abeler VM, McAlpine J, Hoang LN, Huang H-N, Kuo K-T, Lin M-C, Lee C-H. Modern Pathology (In Press).
Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. McAlpine JN, Lisonkova S, Joseph KS, McComb P. Int J Gynecol Cancer. 2014 Oct;24 (8):140613. PMID:25191876.
Quality of Life research in endometrial cancer: what is needed to advance progress in this disease site? McAlpine JN, Greimel E, Brotto LA, Nout RA, Shash E, Avall-Lundqvist E, Friedlander ML, Joly F on behalf of the Gynecologic Cancer Intergroup (GCIG). International Journal Gynecologic Cancer (In Press).
Patient-Reported-Outcomes after treatment of endometrial cancer. Joly F, McAlpine JN, Nout RA, Avall-Lundqvist E, Friedlander ML, and on behalf of the Gynecologic Cancer Intergroup (GCIG). International Journal Gynecologic Cancer (In Press).
Determinants of quality of life in ovarian cancer survivors: A pilot study. Teng FF, Kalloger SE, Brotto, LA, McAlpine JN. J Obstet Gynaecol Can, 2014 Aug;36(8):708-15. PMID:25222166.
Opportunistic salpingectomy: uptake, risks and complications of a regional initiative for ovarian cancer prevention. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Hunstman DG, Miller DM; British Columbia’s Ovarian Cancer Research Program (OVARE). Am J Obstet Gynecol 2014 May;210(5):471.e1-11.PMID: 24412119
The fallopian tube as the origin of high-grade serous ovarian cancer: review of a paradigm shift. Read CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. J Obstet Gynaecol Can 2014 Feb;36(2):133-40. PMID: 24518912
Uterine adenosarcoma: a dual-institution update on staging, prognosis and survival. Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, Ferguson S, Mackay H. Gynecol Oncol 2013 Dec; 131 (3): 634-9. PMID: 24135678.
Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. J Obstet Gynaecol Can 2013 Jul;35(7):627-34. PMID: 23876640
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. J Pathol. 2013 Sep;231(1):21-34. PMID: 23780408
Ovarian and endometrial endometroid carcinomas have distinct CTNNB1 and PTEN mutation profiles. McConechy MK, Ding J, Senz J, Yang W, Melynk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Mod Pathol. 2014 Jan;27(1):128-34. PMID: 23765252.
Clinical trials of palliative chemotherapy in platinum-resistant or –refractory ovarian cancer: time to think differently? Friedlander ML, Stockler MR, Butow P, King MT, McAlpine J, Tinker A, Ledermann JA. J Clin Oncol 2013 Jun;31(18):2362. PMID: 23669225
Opportunistic salpingectomy: the way forward-response to Steven Narod. Miller DM, McAlpine JN, Gilks CB, Huntsman DG. Curr Oncol 2013 Jun;20(3):143-4. PMID: 23737680
Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Hoang LN, McConechy MK, Kobel M, Han G, Rouzbahman M, McAlpine JN, Davidson B, Irving J, Ali RH, Leung S, Liva E, Nucci O, Soslow RA, Huntsman DG, Gilks CB, Lee CH. Am J Surgical Path 2013 Sep;37(9):1421-32. PMID: 24076778
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB. Obstet Gynecol 2013 Jan;121(1):14-24. PMID: 23232752
BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma. Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG. Int J Gynecol Cancer 2013 Jan;23(1):113-118. PMID: 23221734
Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger SE, Senz J, Yang W, Steed H, Ferguson S, Teoman A, Allo G Garcia J, Schoolmeester JK, Shaw P, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman DG, Gilks CB, McAlpine JN. J Pathology. 2013 Jan;229(1):111-20. PMID: 22899400
Report on a molecular quality control exercise performed on specimens from Canadian biobanks partticipating in the COEUR specimen repository. Le Page C, Kobel M, Ladurantage M, Rashimi K, Madore J, Babinszky S, Bachvarov D, Bartlett J, Beauchamp MC, Cass CE, Chadwick D, Crane C, Damarju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piche A, Shaw P, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM. Biopreservation and Biobanking. 2013.11 (2):83-93.
It sounded like a good idea at the time.. Tone A, McAlpine JN, Finlayson S, Gilks CB, Heywood M, Huntsman DG, Miller DM. J Obstet Gynaecol Canada. 2012 Dec34(12):1127-32. PMID 23231793.
Germline mutations in BRCA1 and BRCA2 in ovarian cancer: utility of a histology-based referral strategy. Schrader I, Hurlburt J, Gilks CB, Huntsman DG, McAlpine JN. Obstetrics and Gynecology 2012 Aug;120 (2 Pt 1):235-40.
Use of mutation profiles to refine the classification of endometrial carcinomas. McConechy MK, Ding J, Cheang M, Wiegand K, Senz J, Tone A, Yang W, Prentice L, McAlpine JN Hirst M, Shah S, Lee C, Goodfellow PJ, Gilks CB, Huntsman DG. J Pathology 2012 Sep;228(1):20-30.
The Role of the Fallopian Tube in Ovarian Cancer. Tone A, Salvador S, Finlayson SJ, MD, Tinker AV, Kwon JS, Lee C, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J,Hoskins P, Stuart GC, Swenerton KD,Huntsman DG, Gilks CB, Miller DM, McAlpine, JN. Clinical Advances in Hematologic Oncology 2012 May;10(5):296-306.
BRCA1/2 mutations are only associated with high grade serous subtype of ovarian cancer and correlate with p53 abnormalities and the presence of immune cell infiltrates. McAlpine JN, Porter H, Kalloger SE, Senz, J, Kalloger SE, Nelson B, Prentice L, Ding J, Milne K, Shah SP, Huntsman DG, Gilks CB. Modern Pathology, 2012 May;25(5):740-50.
A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Brotto, L, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, Kwon J, Thomson S, Stuart G, McAlpine JN, Miller DM. Gynecologic Oncology, 2012 May;125(2):320-5.
Bilateral salpingo-oophorectomy and sexual health: A mixed methods study exploring risk-reducing versus benign surgery groups. Brotto L, Branco N, Dunkley C, McCullum M, McAlpine JN. Journal of Obstetrics and Gynaecology Canada, 2012 Feb;34(2):172-8.
14-3-3 fusion oncogenes in endometrial cancer. Lee CH, Chiang S, McAlpine JN, Huntsman DG, Gilks CB, Fletcher J. Proceedings of National Academy of Science, 2012 Jan;109(3):929-34.
Frequency of known gene rearrangements in endometrial stromal tumors. Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E. Am J Surg Pathol. 2011 Sep;35(9):1364-72.
Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Wells T, Plante M, McAlpine JN. Int J Gynecol Cancer, 2011 Aug;21(6):1135-1142.
Identification of Novel Therapeutic Targets in Microdissected Human Clear Cell Ovarian Cancers: A Genomic Approach for Personalized Medicine. Stany M, Ozbun L, Vathipadiekal V, Stone R, Mok S, Xue H, Kagami T, Wang Y, McAlpine JN, Gout P, Miller D, Gilks B, Huntsman D, Ellard S, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood A, Birrer M. PLoS One, 2011;6(7):e21121.
HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target. McAlpine JN, Gilks CB, Histopathology, 2011 Jun;58(7):1173-4.
First-Line Therapy in Ovarian Cancer Trials. Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; on behalf of the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2011 May;21(4):756-762.
Survivorship as an Element of Clinical Trials in Ovarian Cancer. McAlpine JN, Wenzel LB on behalf of the Gynecologic Cancer InterGroup. Int J Gynecol Cancer, 2011 May;21(4):788-792.
The significance of surgical staging in intermediate-risk endometrial cancer. Kwon J, Mazgani M, Miller DM, Ehlen T, Heywood M, McAlpine JN, Finlayson S, Plante M, Stuart G, Carey M. Gynecologic Oncology, 2011 Jul;122(1):50-4.
SOGC-GOC-SCC joint policy statement. Cervical cancer prevention in low-resource settings. Elit L, Jimenez W, McAlpine J, Ghatage P, Miller D, Plante M. J Obstet Gynaecol Can 2011;33(3):272-9.
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG. J Pathol. 2011;223(5):567-73.
Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. McAlpine JN, El-Hallani S, Lam SF, Kalloger SE; Luk M, Huntsman DG, MacAulay, C, Gilks CB, Miller DM, Lane PM. Gynecologic Oncology, 2011;120(3):385-92.
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Kortman U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O’Conner MJ, Huntsman DG, Wang Y, Gilks CB.Clinical Cancer Research, 2011 Feb 15;17(4):783-791.
Teaching cervical cancer surgery in low- or middle-resource countries. Elit E, Rosen B, Jimenez W, Dodge J, Finlayson S, McAlpine JN, Miller DM. Int J Gynecol Cancer, 2010 Dec;20(9):1604-8.
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. BMC Cancer. 2009 Dec 10;9:433.
For a full list of publications please contact the Dr. McAlpine directly.
Canadian Research Society (CRS). Circulating tumour DNA mutations in endometrial and ovarian cancer patients can be used to guide clinical management. PI: McAlpine JN. Co-applicants: Huntsman DG, Gilks CB, Shah SP (2015-2017). $119,147. AWARDED 09/14
Canadian Cancer Society Research Institute (CCSRI). A Population-based assessment of an ovarian cancer prevention program. PI: Huntsman D, McAlpine J. Co-applicants: Coldman A, Gilks B, Miller D, Mitchell G. (2014-2017) $162,307. AWARDED 08/14
Terry Fox Research Institute. Genomics of Frome Fruste Tumours: New Vistas on Cancer Biology and Treatment. Nom PI: Huntsman D. PI: Aparicio S, Hansen C, Hirst M, Lee C-H, Marra M, Morin G, Nielsen T, Shah S, Sorensen P, Underhill TM, Yip S. Co-applicants: Tinker A, McAlpine J, Clarkson P, Schaeffer D. (2014-2019) $7,500,000. AWARDED 07/13
BC Cancer Foundation (BCCF) Sarabjit Gill Memorial Fund, Understanding intra-tumoral heterogeneity within endometrial cancers. Principal Applicant: McAlpine JN (2013-2015). $80,000 AWARDED 07/13
BC Cancer Foundation (BCCF) Funded Project, SMART Cancer Project: Shared Access Medicine an Approach to Rare Tumors Co-Principal Applicants: McAlpine JN and Tinker A. (2013-2016). $264,100 AWARDED 7/13.
Canadian Cancer Society Research Institute (CCSRI) Impact Grant. Contextual genomics: The foundation for subtype specific approaches to ovarian cancer control. PI: Huntsman D. Co-Applicants: Miller D, Morin R, Shah S, McAlpine J, Carey M, Cullis P, Hoskins P, Yong P, Gilks B, Tinker A. (2013-2018) $1,996,690 AWARDED 2/13
Canadian Institute of Health Research (CIHR). PrOTYPE: An Enabling Techology to Imporve Ovarian Cancer Care. PI: Huntsman, DG. Co-Applicants: Anglesio M, McAlpine JN. $159,985. AWARDED 1/13
Physiotherapy Foundation of Canada. Pelvic floor muscle exercises for urinary incontinence in gynecological cancer survivors. Campbell KL. McAlpine J, Brotto L, Finlayson S, Wilson P, Lieblich P, Sran M, Dayan M. Physiotherapy Foundation of Canada, $4000 AWARDED 6/12
Terry Fox Research Institute. Seed/pilot funding for the SMART initiative: Shared Access Medicine for Rare Tumors. PI’s: Tinker A, McAlpine JN, Huntsman DG. $25K/1 year. AWARDED 12/11.
British Columbia Ovarian Cancer Research (OvCaRe) and Carraresi Foundation. High grade serous carcinomas with ovarian and endometrial involvement: characterization, determination of site of origin, and a step towards a better classification system. PI: McAlpine JN, Co-Applicant: Gilks CB. ~9K/2 year. AWARDED 1/12.
British Columbia Ovarian Cancer Research (OvCaRe) and Carraresi Foundation Salpingectomy for risk reduction in BRCA1/2 mutation carriers: a cost analysis. PI: Kwon J, Co-Applicant: McAlpine JN. ~12K/2 year. AWARDED 1/12.
CIHR Operating Grant March 2011. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? PI’s: Shah SP, McAlpine JN. $563,330/4 years. AWARDED 6/11.
Martha Piper Research Fund: Selective Excitation Light Fluorescence (SELF) Imaging In Vivo PI: Calum MacAulay Co-Applicant McAlpine JN $23,450. AWARDED 04/11.
Genzyme Biosurgery (Investigator Initiated Research Grant). Seprafilm™ for the prevention of intraperitoneal adhesions and improved delivery of therapy in women undergoing surgical staging and intraperitoneal chemotherapy for advanced ovarian cancer. PI: McAlpine ~$22,000 ($40,000 minus product). AWARDED 4/09. Closed Dec 2013.
Ovarian Cancer Canada. Pilot project funding. Ovarian Cancer Early Screening Project (OCESP): Lower genital tract secretions for early screening of pelvic epithelial cancers. PI: J.N. McAlpine JN $30,000 AWARDED 6/08 (completed)
Merck (US-Investigator Initiated Research Grant). The Impact of Bisphosphonates on bone loss in patients undergoing surgery and postoperative chemotherapy for gynecologic malignancies.
PI: McAlpine JN 2005 USA and awarded in Canada 5/08, ~$32,000 (closed)
Canadian Institutes of Health Research (CIHR). A Study of the Immunobiology of an HPV VLP Vaccine in a Cohort of HIV Positive Girls and Women. PI: Money D.Collaborator: McAlpine JN. ~$1,389,043 over 5 years. AWARDED 3/08.
CIHR New Investigator Award. Genomic Disruption in High-Grade Serous Ovarian Carcinomas: Steady State or Continuous Drift? McAlpine JN $60,000/year x5 years. AWARDED 6/12.
Vancouver Coastal Health Research Institute In it For Life Mentored Clinical Scientist Award, 2008. PARP inhibitors in epithelial ovarian cancer: targeted molecular therapy in BRCA null phenotypes and mechanisms of resistance. PI: J.N. McAlpine $50,000/year (granted 3 years). AWARDED 6/08.